Overview: Translating Hsp90 biology into Hsp90 drugs

Current Cancer Drug Targets

Volumn 3, Issue 5, 2003, Pages 297-300

  Workman, Paul ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATASE; ADENOSINE TRIPHOSPHATASE INHIBITOR; ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GELDANAMYCIN; HEAT SHOCK PROTEIN 90; MUTANT PROTEIN; PROTEIN P53; RADICICOL; RAF PROTEIN; TELOMERASE; UNCLASSIFIED DRUG;

AMINO TERMINAL SEQUENCE; ANTINEOPLASTIC ACTIVITY; CANCER; CANCER CELL; CANCER PATIENT; CLINICAL TRIAL; DRUG PROTEIN BINDING; DRUG TARGETING; ENZYME INHIBITION; HEAT SHOCK; HUMAN; INDUCED MUTATION; MICROENVIRONMENT; MULTIPLE CANCER; PROTEIN CONFORMATION; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN STABILITY; REVIEW; STRESS; X RAY CRYSTALLOGRAPHY;

ANIMALS; ANTI-BACTERIAL AGENTS; ANTINEOPLASTIC AGENTS; BENZOQUINONES; DRUG DELIVERY SYSTEMS; HSP90 HEAT-SHOCK PROTEINS; HUMANS; LACTAMS, MACROCYCLIC; MOLECULAR CHAPERONES; RIFABUTIN;

EID: 0141596941     PISSN: 15680096     EISSN: None     Source Type: Journal    
DOI: 10.2174/1568009033481868     Document Type: Review

References (8)

1. Rutherford, S. L.; Lindquists, S. Hsp90 as a Capacitor for Morphological Evolution. Nature 1998, 396, 336-342.
2. Queitsch, C.; Sangster, T. A.; Lindquist, S. Hsp90 as a Capacitor of Phenotypic Variation. Nature 2002, 417, 618-624.
3. Sangster, T. A.; Queitsch, C.; Lindquist, S. Hsp90 and Chromatin. Where is the Link? Cell Cycle 2003, 23, 166-168
4. Hanahan, D.; Weinberg, R. A. The Hallmarks of Cancer. Cell 2000, 100, 57-70.
5. Maloney, A.; Workman, P. HSP90 as a New Therapeutic Target for Cancer Therapy: The Story Unfolds. Expert. Opin. Biol. Ther. 2002, 2:3-24.
6. Issacs, J. S.; Xu, W.; Neckers, L. Heat Shock Protein 90 as a Molecular Target for Cancer Therapeutics. Cancer Cell 2003, 3 213-217.
7. Davies, H.; Bignell, G. R.; Cox, C.; Stephens, P.; Edkins, S.; Clegg, S. ; Teague, J.; Woffendin, H.; Garnett, M. J.; Bottomley, W.; Davis, N.; Dicks, E.; Ewing, R.; Floyd, Y.; Gray, K.; Hall, S.; Hawes, R.; Hughes, J.; Kosmidou, V.; Menzies, A.; Mould, C.; Parker, A.; Stevens, C.; Watt, S.; Hooper, S.; Wilson, R.; Jayatilake, H.; Gusterson, B. A.; Cooper, C.; Shipley, J.; Hargrave, D.; Pritchard-Jones, K.; Maitland, N.; Chenevix-Trench, G.; Riggins, G. J.; Bigner, D. D.; Palmieri, G.; Cossu, A.; Flanagan, A.; Nicholson, A.; Ho, J. W. C.; Leung, S. Y.; Yuen, S. T.; Weber, B. L.; Seigler, H. F.; Darrow, T. L.; Paterson, H.; Marais, R.; Marshall, C. J.; Wooster, R.; Stratton, M. R.; Futreal, A. Mutations of the BRAF Gene in Human Cancer. Nature, 2002, 417, 949-954
8. Workman, P. Cancer Genome Targets: RAF-ing Up Tumour Cells to Overcome Oncogene Addiction. Exp. Rev. Anticancer Ther. 2002, 2, 611-614.